PT-141, also known as Bremelanotide, is a synthetic peptide that functions as a melanocortin receptor agonist. It was initially developed as a treatment for sexual dysfunction, specifically for individuals with hypoactive sexual desire disorder (HSDD).
PT-141 acts on melanocortin receptors in the central nervous system, stimulating the release of neurotransmitters involved in sexual arousal and desire. It increases dopamine activity, which plays a crucial role in regulating sexual motivation and pleasure.
Unlike other medications for sexual dysfunction, PT-141 does not target the vascular system but acts directly on the brain to enhance sexual desire.
It is administered as a subcutaneous injection and typically begins to take effect within a few hours.
Studies have shown that PT-141 has potential benefits for both men and women, addressing various forms of sexual dysfunction. It has demonstrated efficacy in improving sexual desire, arousal, and satisfaction
The science behind PT-141 (Bremelanotide) involves its interaction with melanocortin receptors in the brain.
PT-141 is a peptide that acts as a selective agonist for the melanocortin-4 receptor (MC4R) and, to a lesser extent, the melanocortin-3 receptor (MC3R). These receptors are found in the central nervous system and play a role in regulating sexual arousal and desire.
When PT-141 binds to the MC4R and MC3R, it activates a signaling cascade that leads to the release of various neurotransmitters, including dopamine, in the brain. Dopamine is involved in the reward and pleasure pathways and plays a significant role in sexual motivation and desire.
By increasing dopamine activity, PT-141 enhances sexual arousal and desire. It helps to address sexual dysfunction by improving the neurochemical processes involved in sexual response.
PT-141 is different from traditional treatments for sexual dysfunction, such as phosphodiesterase type 5 (PDE5) inhibitors like Viagra. While PDE5 inhibitors primarily target the vascular system to improve blood flow, PT-141 acts directly on the brain to enhance sexual desire.
- Increases sexual desire and arousal
- Enhances sexual pleasure and satisfaction
- Addresses sexual dysfunction, including hypoactive sexual desire disorder (HSDD)
- Acts directly on the brain to improve sexual motivation
- Potential benefits for both men and women
- Administered through subcutaneous injection
Vial size: 10mg
Recommended dose: 1mg (may increase to 4mg for individuals with erectile dysfunction)
Administration frequency: Once every 24 hours, with a maximum of 8 doses per month
Administration timing: 45 minutes before adult activity
Onset of effects: Effects may be noticeable within minutes to a few hours
Duration of effects: Effects may last up to 24 hours, with some men reporting longer-lasting erections of 2-6 hours
PT-141 works by stimulating melanocortin receptors in the brain, specifically the melanocortin-4 receptor (MC4R). By activating these receptors, PT-141 enhances the release of dopamine, a neurotransmitter involved in sexual motivation and desire.
Yes, PT-141 has shown potential benefits for both men and women. It can address sexual dysfunction and increase sexual desire in individuals of both genders.